Research Analysts Set Expectations for TCRX FY2028 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Investment analysts at Wedbush raised their FY2028 earnings estimates for TScan Therapeutics in a research note issued on Tuesday, November 12th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $0.46 per share for the year, up from their previous estimate of $0.40. Wedbush has a “Outperform” rating and a $10.00 price target on the stock. The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share.

TScan Therapeutics (NASDAQ:TCRX) last announced its earnings results on Monday, August 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.02. The company had revenue of $0.54 million during the quarter, compared to analyst estimates of $1.55 million. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 63.11%.

Other analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and issued a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $12.00.

TScan Therapeutics Stock Performance

Shares of NASDAQ TCRX opened at $4.82 on Thursday. The stock’s 50-day moving average is $5.33 and its 200 day moving average is $6.51. The stock has a market cap of $255.32 million, a price-to-earnings ratio of -4.55 and a beta of 0.79. TScan Therapeutics has a 1-year low of $3.73 and a 1-year high of $9.69. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08.

Insider Activity

In other news, insider Zoran Zdraveski sold 164,686 shares of the business’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the transaction, the insider now directly owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Barbara Klencke purchased 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were purchased at an average price of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $221,200. This represents a 14.29 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 15,000 shares of company stock valued at $82,550. Company insiders own 2.76% of the company’s stock.

Institutional Investors Weigh In On TScan Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP bought a new stake in TScan Therapeutics in the second quarter worth $70,000. The Manufacturers Life Insurance Company bought a new stake in TScan Therapeutics in the second quarter worth $90,000. SG Americas Securities LLC bought a new stake in TScan Therapeutics in the third quarter worth $78,000. Cornercap Investment Counsel Inc. bought a new stake in TScan Therapeutics in the second quarter worth $134,000. Finally, MetLife Investment Management LLC boosted its holdings in TScan Therapeutics by 129.1% in the third quarter. MetLife Investment Management LLC now owns 23,363 shares of the company’s stock worth $116,000 after acquiring an additional 13,164 shares in the last quarter. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.